Pegvisomant therapy in acromegalic patient resistant to other treatment: case report

Nowicka Emilia, Obel Michał, Dzikowski Piotr, Stefaniak Martyna, Pietrzak Zofia, Obel Ewa. Pegvisomant therapy in acromegalic patient resistant to other treatment: case report. Journal of Education, Health and Sport. 2022;12(8):99-106. eISSN 2391-8306. DOI https://dx.doi.org/10.12775/JEHS.2022.12.08.010

https://apcz.umk.pl/JEHS/article/view/JEHS.2022.12.08.010

https://zenodo.org/record/6618077

 

 

 

 

 

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343.

Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences).

 

Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159.

Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

 

© The Authors 2022;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

 

Received: 12.05.2022. Revised: 25.05.2022. Accepted: 06.06.2022.

 

 

 

 

 

Pegvisomant therapy in acromegalic patient resistant to other treatment: case report

 

Emilia Nowicka¹, e.nowicka22@gmail.com;

https://orcid.org/0000-0002-2743-1551

Michał Obel¹, michalobel3@gmail.com;

https://orcid.org/0000-0003-1237-8732

Piotr Dzikowski², piotrekdzikowski22@gmail.com;

https://orcid.org/0000-0002-6335-9171

Martyna Stefaniak², martynastefaniakk@gmail.com;

https://orcid.org/0000-0002-8036-8379

Zofia Pietrzak², zofer.pietrzak@gmail.com

https://orcid.org/0000-0001-8469-6225

Ewa Obel³, obel.ewa@wp.pl;

https://orcid.org/0000-0003-2961-8843

 

1. Students’ Scientific Association at the Department of Endorinology of the Medical University of Lublin

2. Students’ Scientific Association at the Chair and Department of Epidemiology of Medical University of Lublin

3. Department of Endorinology of the Medical University of Lublin

 

 

 

Abstract

 

Introduction: Acromegaly is a chronic, rare disorder resulting from growth hormone (GH) hypersecretion, usually caused by a pituitary adenoma. GH stimulates synthesis of insulin-like growth factor 1 (IGF-1), whom assay should be used as a screening test whenever acromegaly is suspected. Patients with acromegaly normally take from 5 to 10 years to receive a correct diagnosis, leading to complications such as cardiovascuar, respiratory, and endocrine problems that are responsible for an increase mortality. Late diagnosis of the disease also impact the effectiveness of surgical, pharmacological and radiotherapy treatment. 

 

Case report: A 33-year-old acromegalic man with pituitary macroadenoma resistant to therapy of somastatin analogue (octreotide, lanreotide) and dopamine agonist (cabergoline). The patient underwent transsphenoidal adenomectomy, after wich high level of GH and IGF-1 were still measured. Due to the lack of the effect of the current treatment, the patient was qualified for pegvisomant therapy, as a result of which biochemical control was achieved without adverse events and with a good compliance of treatment. 

 

Conclusions: Treatment with pegvisomant is now an important therapeutic strategy to achieve full disease control in acromegalic patients resistant or poorly responders to first generation somatostatin receptor ligands and in patients who do not respond adequately to selective excision of pituitary adenoma and /or for whom surgery is not possible.

 

Key words: acromegaly; treatment; pegvisomant; pituitary macroadenoma;